Alliancebernstein L.P. Genmab A/S Call Options Transaction History
Alliancebernstein L.P.
- $261 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding GMAB
# of Institutions
247Shares Held
66.2MCall Options Held
729KPut Options Held
398K-
Orbis Allan Gray LTD Hamilton, D05.71MShares$117 Million0.8% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$104 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.43MShares$90.8 Million0.02% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.88MShares$59.1 Million0.45% of portfolio
-
Morgan Stanley New York, NY2.84MShares$58.3 Million0.0% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $13.5B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...